A phase 2b, randomised, double-blind, active controlled, multi centre study to evaluate the efficacy, safety and tolerability of oral AZD9977 and dapagliflozin treatment in patients with heart failure

11 May 2024 (13:45 - 13:53)

Organised by:

Video

Sign in for access options

Slides

About the speaker

Professor Carolyn S P Lam

Duke-NUS Graduate Medical School Singapore, Singapore (Singapore)

9 More presentations in this session

Presentation thumbnail

Discussant review - MIRACLE

Professor M. Packer (Dallas, US)

Presentation thumbnail

A phase 2, randomized, double-blind, placebo-controlled study to assess the tolerability and pharmacodynamic effects of CRD-740, a PDE9 inhibitor, in participants with chronic heart failure

Professor J. Udelson (Boston, US)

Presentation thumbnail

Discussant review - CARDINAL HF

Associate Professor A. Bohm (Bratislava, SK)

Presentation thumbnail

Readily available urinary sodium analysis in patients with acute decompensate Heart Failure

Doctor E. Meekers (Genk, BE)

Presentation thumbnail

Discussant review - EASY-HF

Doctor P. Pellicori (Glasgow, GB)

Access the full session

Session thumbnail

Late breaking clinical trials: medical therapy

The Event

Event poster

Heart Failure 2024

11 May 2024 13:45 CET

You may be interested in

Congress Presentation

A phase 2, randomized, double-blind, placebo-controlled study to assess the tolerability and pharmacodynamic effects of CRD-740, a PDE9 inhibitor, in participants with chronic heart failure

Congress Presentation

Discussant review - CARDINAL HF

ESC Journals

A phase 2, randomized, double-blind, placebo-controlled study to assess the tolerability and pharmacodynamic effects of CRD-740, a PDE9 inhibitor, in participants with chronic heart failure

ESC 365 is supported by

novartis

Explore sponsored resources

ESC 365 is supported by

novartis

Explore sponsored resources